Velan Capital Investment Management LP Purchases Shares of 70,000 Regulus Therapeutics Inc. (NASDAQ:RGLS)

Velan Capital Investment Management LP bought a new position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 70,000 shares of the biopharmaceutical company's stock, valued at approximately $111,000. Regulus Therapeutics accounts for about 0.1% of Velan Capital Investment Management LP's investment portfolio, making the stock its 24th largest holding. Velan Capital Investment Management LP owned about 0.11% of Regulus Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. PEAK6 LLC purchased a new position in shares of Regulus Therapeutics during the fourth quarter valued at $95,000. JPMorgan Chase & Co. increased its stake in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 52,059 shares during the period. Barclays PLC increased its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 62,549 shares during the period. Renaissance Technologies LLC increased its stake in shares of Regulus Therapeutics by 20.5% during the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after buying an additional 19,900 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after buying an additional 900,743 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Price Performance

NASDAQ RGLS traded down $0.02 during trading on Friday, hitting $7.89. The company's stock had a trading volume of 1,814,371 shares, compared to its average volume of 902,748. The company has a market cap of $546.26 million, a PE ratio of -7.37 and a beta of 0.49. The business's 50 day simple moving average is $4.06 and its 200-day simple moving average is $2.32. Regulus Therapeutics Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $8.20.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. Analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

RGLS has been the topic of several analyst reports. Wells Fargo & Company reiterated an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research note on Thursday, May 1st. Leerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Wall Street Zen initiated coverage on Regulus Therapeutics in a research note on Sunday, May 18th. They issued a "sell" rating on the stock. Jones Trading reiterated a "hold" rating and issued a $7.00 target price (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Finally, Canaccord Genuity Group reiterated a "hold" rating and issued a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.50.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.